Shukra Pharma Confirms Receipt of Differential Warrant Consideration

Shukra Pharmaceuticals Limited announced that its Board of Directors, in a meeting held on July 14, 2026, confirmed the receipt of differential upfront consideration for 46,43,000 convertible equity warrants. The allottees paid an additional amount of Rs. 0.39 per warrant, totaling Rs. 18,10,770, to account for a re-computation of the issue price from Rs. 34.00 to Rs. 35.56 per warrant. This payment was made within the stipulated 15-day period from the special resolution date. Additionally, two allottees paid the remaining 75% of the differential upfront amount, aggregating to Rs. 20,29,950. These actions ensure full compliance with SEBI ICDR Regulations.